Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given an average rating of “Buy” by the six ratings firms that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $19.50.

Several brokerages have recently weighed in on ZVRA. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, April 3rd. William Blair reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th. Maxim Group upped their price target on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research report on Monday, April 1st.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently bought and sold shares of the company. VisionPoint Advisory Group LLC acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $33,000. International Assets Investment Management LLC increased its stake in Zevra Therapeutics by 555.0% in the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock valued at $43,000 after buying an additional 5,550 shares during the period. Tower Research Capital LLC TRC increased its stake in Zevra Therapeutics by 134.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock valued at $63,000 after buying an additional 5,545 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Zevra Therapeutics in the 1st quarter valued at $64,000. Finally, IFG Advisors LLC grew its stake in shares of Zevra Therapeutics by 45.0% during the 1st quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after purchasing an additional 5,800 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Down 2.2 %

Shares of Zevra Therapeutics stock opened at $4.45 on Thursday. The company has a market capitalization of $186.23 million, a P/E ratio of -3.30 and a beta of 1.96. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.88. Zevra Therapeutics has a 52-week low of $3.89 and a 52-week high of $7.28. The company has a 50 day moving average of $4.72 and a 200 day moving average of $5.43.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09. The business had revenue of $3.43 million during the quarter, compared to the consensus estimate of $3.52 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. As a group, research analysts forecast that Zevra Therapeutics will post -1.54 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.